+Follow
神秘紫
No personal profile
2
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
神秘紫
2021-07-06
Nice
AGCO Baifa IPO in Hong Kong: annual loss of 91.63 million, product has not yet been commercialized
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4087179126205260","uuid":"4087179126205260","gmtCreate":1624104992309,"gmtModify":1624880835567,"name":"神秘紫","pinyin":"smzshenmizi","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/8a1a172d1a6a97bd0845231616bcef1e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":2,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":157350240,"gmtCreate":1625568030480,"gmtModify":1703743904325,"author":{"id":"4087179126205260","authorId":"4087179126205260","name":"神秘紫","avatar":"https://static.tigerbbs.com/8a1a172d1a6a97bd0845231616bcef1e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087179126205260","idStr":"4087179126205260"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157350240","repostId":"2149333886","repostType":4,"repost":{"id":"2149333886","kind":"highlight","pubTimestamp":1625567714,"share":"https://ttm.financial/m/news/2149333886?lang=en_US&edition=fundamental","pubTime":"2021-07-06 18:35","market":"hk","language":"zh","title":"AGCO Baifa IPO in Hong Kong: annual loss of 91.63 million, product has not yet been commercialized","url":"https://stock-news.laohu8.com/highlight/detail?id=2149333886","media":"格隆汇","summary":"上海爱科百发生物医药技术股份有限公司（以下简称“爱科百发”）向港交所递交上市招股说明书，美银、中信证券和华兴资本担任联席保荐人，德勤为其审计师。\n自2014年成立以来，爱科百发共开展了8轮融资。在最新","content":"<p>Shanghai AGCO Baifa Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as \"AGCO Baifa\") submitted a listing prospectus to the Hong Kong Stock Exchange, Bank of America,<a href=\"https://laohu8.com/S/600030\">CITIC Securities</a>And China Renaissance Capital as joint sponsors, with Deloitte as its auditor.</p><p>Since its establishment in 2014, AGCO Baifa has carried out<b>8 rounds of financing</b>。 In the latest C + round of financing, in January 2021, the company introduced Hillhouse Venture Capital and TPG to jointly lead the investment, and 8 investment institutions including Wanrong Hongtu, Ruihua Investment, and Yanyuan Yaoshang participated in the investment.<b>After financing, the company's valuation reached 3.87 billion yuan</b>。</p><p>Before the IPO, in terms of the company's shareholding structure, Dr. Jim Zhen WU held 19.58% of the shares through the wholly-owned Prots Excel, 4.99% of the shares through the wholly-owned Million Joy, and 2.65% of the shares through the 99.99% of the shares. Owns 27.22% of the shares; The four employee stock ownership plan platforms hold a total of 7.96% of the shares; Among institutional investors,<b>Qiming Venture Capital holds the largest share, reaching 11.11%</b>； Taifu Capital holds a total of 7.84% of the shares through Golden Trend and HarmonySky; Morningside Capital holds 7.51% of the shares through Yaoyang Biotechnology;<b>Hillhouse Capital and TPG each hold 4.99% of the company's equity</b>In addition, other shareholders hold approximately 31% of the shares.</p><p><img src=\"https://static.tigerbbs.com/7b431d82c25aa99e56762dcca708a2c2\" tg-width=\"1118\" tg-height=\"676\" referrerpolicy=\"no-referrer\"></p><p>In terms of business, AGCO Baifa, as an innovative biopharmaceutical company, focuses on discovering and developing new therapies to meet the unmet medical needs of respiratory and lung diseases.</p><p>At present, AGCO Baifa has developed<b>Pipeline of 9 drug candidates</b>, the core products include a three-drug RSV drug portfolio led by Ziresovir, and a three-drug anti-fibrotic drug portfolio focusing on AK3280. In addition, the company has a number of drugs under development in the fields of pulmonary fibrosis and inflammation, liver and other diseases that are in the preclinical or clinical stage, and there is still a long time before they are launched.</p><p><img src=\"https://static.tigerbbs.com/1abd4768a9678b36257ed9350d5fec2e\" tg-width=\"1064\" tg-height=\"669\" referrerpolicy=\"no-referrer\"></p><p>In 2020, the global RSV drug market was USD 1.8 billion,<b>Expected to grow to $1.8 billion by 2030</b>, with a compound annual growth rate of 21.4%. At present,<b>There is no effective treatment for RSV on the market</b>。 Ziresovir, which is being developed by AGCO Baifa, is the world's first RSV drug to successfully complete a phase II proof-of-concept clinical trial for hospitalized infants and young children.</p><p>Clinical trials have shown that after taking multiple doses of Ziresovir, patients have strong antiviral effects. Compared with the placebo group, the viral load of the drug treatment group is reduced by up to 98%, showing good efficacy and safety. At present,<b>AK0529 drug (Ziresovir) for pediatric RSV is already in clinical phase III and is expected to submit a new drug application to the State Food and Drug Administration in the second half of 2022 and be launched domestically in 2023.</b></p><p><img src=\"https://static.tigerbbs.com/adefd4a0d734b6768bbede484a81ad6e\" tg-width=\"773\" tg-height=\"704\" referrerpolicy=\"no-referrer\"></p><p>For now, AGCO Baifa has not yet launched any products for commercialization.<b>Still in the red</b>。 The prospectus shows that the company had no revenue in 2019, and its revenue in 2020 was 14.15 million yuan; The corresponding net losses were 112 million yuan and 91.628 million yuan respectively.<b>As of the first quarter of 2021, the company's loss scale has doubled from the same period last year to 35.258 million yuan</b>。 It is foreseeable that in a short period of time, the company's \"burning money\" research and development situation will continue.</p>","source":"gelonghui_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AGCO Baifa IPO in Hong Kong: annual loss of 91.63 million, product has not yet been commercialized</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAGCO Baifa IPO in Hong Kong: annual loss of 91.63 million, product has not yet been commercialized\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">格隆汇</strong><span class=\"h-time small\">2021-07-06 18:35</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Shanghai AGCO Baifa Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as \"AGCO Baifa\") submitted a listing prospectus to the Hong Kong Stock Exchange, Bank of America,<a href=\"https://laohu8.com/S/600030\">CITIC Securities</a>And China Renaissance Capital as joint sponsors, with Deloitte as its auditor.</p><p>Since its establishment in 2014, AGCO Baifa has carried out<b>8 rounds of financing</b>。 In the latest C + round of financing, in January 2021, the company introduced Hillhouse Venture Capital and TPG to jointly lead the investment, and 8 investment institutions including Wanrong Hongtu, Ruihua Investment, and Yanyuan Yaoshang participated in the investment.<b>After financing, the company's valuation reached 3.87 billion yuan</b>。</p><p>Before the IPO, in terms of the company's shareholding structure, Dr. Jim Zhen WU held 19.58% of the shares through the wholly-owned Prots Excel, 4.99% of the shares through the wholly-owned Million Joy, and 2.65% of the shares through the 99.99% of the shares. Owns 27.22% of the shares; The four employee stock ownership plan platforms hold a total of 7.96% of the shares; Among institutional investors,<b>Qiming Venture Capital holds the largest share, reaching 11.11%</b>； Taifu Capital holds a total of 7.84% of the shares through Golden Trend and HarmonySky; Morningside Capital holds 7.51% of the shares through Yaoyang Biotechnology;<b>Hillhouse Capital and TPG each hold 4.99% of the company's equity</b>In addition, other shareholders hold approximately 31% of the shares.</p><p><img src=\"https://static.tigerbbs.com/7b431d82c25aa99e56762dcca708a2c2\" tg-width=\"1118\" tg-height=\"676\" referrerpolicy=\"no-referrer\"></p><p>In terms of business, AGCO Baifa, as an innovative biopharmaceutical company, focuses on discovering and developing new therapies to meet the unmet medical needs of respiratory and lung diseases.</p><p>At present, AGCO Baifa has developed<b>Pipeline of 9 drug candidates</b>, the core products include a three-drug RSV drug portfolio led by Ziresovir, and a three-drug anti-fibrotic drug portfolio focusing on AK3280. In addition, the company has a number of drugs under development in the fields of pulmonary fibrosis and inflammation, liver and other diseases that are in the preclinical or clinical stage, and there is still a long time before they are launched.</p><p><img src=\"https://static.tigerbbs.com/1abd4768a9678b36257ed9350d5fec2e\" tg-width=\"1064\" tg-height=\"669\" referrerpolicy=\"no-referrer\"></p><p>In 2020, the global RSV drug market was USD 1.8 billion,<b>Expected to grow to $1.8 billion by 2030</b>, with a compound annual growth rate of 21.4%. At present,<b>There is no effective treatment for RSV on the market</b>。 Ziresovir, which is being developed by AGCO Baifa, is the world's first RSV drug to successfully complete a phase II proof-of-concept clinical trial for hospitalized infants and young children.</p><p>Clinical trials have shown that after taking multiple doses of Ziresovir, patients have strong antiviral effects. Compared with the placebo group, the viral load of the drug treatment group is reduced by up to 98%, showing good efficacy and safety. At present,<b>AK0529 drug (Ziresovir) for pediatric RSV is already in clinical phase III and is expected to submit a new drug application to the State Food and Drug Administration in the second half of 2022 and be launched domestically in 2023.</b></p><p><img src=\"https://static.tigerbbs.com/adefd4a0d734b6768bbede484a81ad6e\" tg-width=\"773\" tg-height=\"704\" referrerpolicy=\"no-referrer\"></p><p>For now, AGCO Baifa has not yet launched any products for commercialization.<b>Still in the red</b>。 The prospectus shows that the company had no revenue in 2019, and its revenue in 2020 was 14.15 million yuan; The corresponding net losses were 112 million yuan and 91.628 million yuan respectively.<b>As of the first quarter of 2021, the company's loss scale has doubled from the same period last year to 35.258 million yuan</b>。 It is foreseeable that in a short period of time, the company's \"burning money\" research and development situation will continue.</p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.gelonghui.com/p/473496\">格隆汇</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","relate_stocks":{"HSI":"恒生指数"},"source_url":"http://www.gelonghui.com/p/473496","is_english":false,"share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","article_id":"2149333886","content_text":"上海爱科百发生物医药技术股份有限公司（以下简称“爱科百发”）向港交所递交上市招股说明书，美银、中信证券和华兴资本担任联席保荐人，德勤为其审计师。\n自2014年成立以来，爱科百发共开展了8轮融资。在最新的C+轮融资中，2021年1月，公司引入高瓴创投、TPG联合领投，万容红土、瑞华投资、燕园姚商等8家投资机构参与投资，融资后公司估值达到38.7亿元。\nIPO前，公司股权架构方面，Jim Zhen WU博士通过全资拥有的Prots Excel持股19.58%，通过全资拥有的Million Joy持股4.99%，通过持股99.99%的爱尔凯持股2.65%，合计拥有股份27.22%；4个雇员持股计划平台合计持股7.96%；机构投资者中，启明创投持股占比最大，达11.11%；泰福资本通过Golden Trend、HarmonySky合计持股7.84%；晨兴资本通过耀阳生物科技持股7.51%；高瓴资本、TPG各持有公司4.99%股权，除此之外，其他股东持股约31%。\n\n业务方面，爱科百发作为一家创新生物制药公司，专注于发现和开发新型疗法，以应对呼吸系统和肺部疾病方面未被满足的医疗需求。\n目前，爱科百发已开发了9种候选药物的产品管线，核心产品包括以Ziresovir为首的三项药物RSV药品组合，以及以AK3280为重点的三项药物的抗纤维化药品组合。除此之外，公司在肺纤维化和炎症、肝脏及其他疾病领域还有多款在研药品处于临床前或临床阶段，离上市还有很长的时间。\n\n2020年，全球RSV药物市场为18亿美元，预计到2030年将增长至18亿美元，年复合增长率为21.4%。目前，市场上还没有有效的RSV治疗方法。而爱科百发正研发的Ziresovir是全球首款成功完成住院婴幼儿II期概念验证临床试验的RSV药物。\n临床试验显示，多剂量服用Ziresovir后，患者体内有强抗病毒作用，与安慰剂组相比，药物治疗组的病毒载量最多减少98%，显示出良好的疗效及安全性。目前，针对儿童RSV的AK0529药物（Ziresovir）已处于临床III期，预计将于2022年下半年向国家药监局提交新药申请，并于2023年在国内上市。\n\n就目前而言，爱科百发尚未有产品上市商业化，仍处于亏损状态。招股书显示，公司2019年无营收，2020年营收为1415万元；相对应的净亏损分别为1.12亿元、9162.8万元。截至2021年一季度，公司亏损规模较上年同期扩大1倍至3525.8万元。可以预见的是，短时间内，公司“烧钱”研发的状况仍将持续。","news_type":1,"symbols_score_info":{"HSI":0.9}},"isVote":1,"tweetType":1,"viewCount":1852,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":157350240,"gmtCreate":1625568030480,"gmtModify":1703743904325,"author":{"id":"4087179126205260","authorId":"4087179126205260","name":"神秘紫","avatar":"https://static.tigerbbs.com/8a1a172d1a6a97bd0845231616bcef1e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087179126205260","idStr":"4087179126205260"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157350240","repostId":"2149333886","repostType":4,"repost":{"id":"2149333886","kind":"highlight","pubTimestamp":1625567714,"share":"https://ttm.financial/m/news/2149333886?lang=en_US&edition=fundamental","pubTime":"2021-07-06 18:35","market":"hk","language":"zh","title":"AGCO Baifa IPO in Hong Kong: annual loss of 91.63 million, product has not yet been commercialized","url":"https://stock-news.laohu8.com/highlight/detail?id=2149333886","media":"格隆汇","summary":"上海爱科百发生物医药技术股份有限公司（以下简称“爱科百发”）向港交所递交上市招股说明书，美银、中信证券和华兴资本担任联席保荐人，德勤为其审计师。\n自2014年成立以来，爱科百发共开展了8轮融资。在最新","content":"<p>Shanghai AGCO Baifa Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as \"AGCO Baifa\") submitted a listing prospectus to the Hong Kong Stock Exchange, Bank of America,<a href=\"https://laohu8.com/S/600030\">CITIC Securities</a>And China Renaissance Capital as joint sponsors, with Deloitte as its auditor.</p><p>Since its establishment in 2014, AGCO Baifa has carried out<b>8 rounds of financing</b>。 In the latest C + round of financing, in January 2021, the company introduced Hillhouse Venture Capital and TPG to jointly lead the investment, and 8 investment institutions including Wanrong Hongtu, Ruihua Investment, and Yanyuan Yaoshang participated in the investment.<b>After financing, the company's valuation reached 3.87 billion yuan</b>。</p><p>Before the IPO, in terms of the company's shareholding structure, Dr. Jim Zhen WU held 19.58% of the shares through the wholly-owned Prots Excel, 4.99% of the shares through the wholly-owned Million Joy, and 2.65% of the shares through the 99.99% of the shares. Owns 27.22% of the shares; The four employee stock ownership plan platforms hold a total of 7.96% of the shares; Among institutional investors,<b>Qiming Venture Capital holds the largest share, reaching 11.11%</b>； Taifu Capital holds a total of 7.84% of the shares through Golden Trend and HarmonySky; Morningside Capital holds 7.51% of the shares through Yaoyang Biotechnology;<b>Hillhouse Capital and TPG each hold 4.99% of the company's equity</b>In addition, other shareholders hold approximately 31% of the shares.</p><p><img src=\"https://static.tigerbbs.com/7b431d82c25aa99e56762dcca708a2c2\" tg-width=\"1118\" tg-height=\"676\" referrerpolicy=\"no-referrer\"></p><p>In terms of business, AGCO Baifa, as an innovative biopharmaceutical company, focuses on discovering and developing new therapies to meet the unmet medical needs of respiratory and lung diseases.</p><p>At present, AGCO Baifa has developed<b>Pipeline of 9 drug candidates</b>, the core products include a three-drug RSV drug portfolio led by Ziresovir, and a three-drug anti-fibrotic drug portfolio focusing on AK3280. In addition, the company has a number of drugs under development in the fields of pulmonary fibrosis and inflammation, liver and other diseases that are in the preclinical or clinical stage, and there is still a long time before they are launched.</p><p><img src=\"https://static.tigerbbs.com/1abd4768a9678b36257ed9350d5fec2e\" tg-width=\"1064\" tg-height=\"669\" referrerpolicy=\"no-referrer\"></p><p>In 2020, the global RSV drug market was USD 1.8 billion,<b>Expected to grow to $1.8 billion by 2030</b>, with a compound annual growth rate of 21.4%. At present,<b>There is no effective treatment for RSV on the market</b>。 Ziresovir, which is being developed by AGCO Baifa, is the world's first RSV drug to successfully complete a phase II proof-of-concept clinical trial for hospitalized infants and young children.</p><p>Clinical trials have shown that after taking multiple doses of Ziresovir, patients have strong antiviral effects. Compared with the placebo group, the viral load of the drug treatment group is reduced by up to 98%, showing good efficacy and safety. At present,<b>AK0529 drug (Ziresovir) for pediatric RSV is already in clinical phase III and is expected to submit a new drug application to the State Food and Drug Administration in the second half of 2022 and be launched domestically in 2023.</b></p><p><img src=\"https://static.tigerbbs.com/adefd4a0d734b6768bbede484a81ad6e\" tg-width=\"773\" tg-height=\"704\" referrerpolicy=\"no-referrer\"></p><p>For now, AGCO Baifa has not yet launched any products for commercialization.<b>Still in the red</b>。 The prospectus shows that the company had no revenue in 2019, and its revenue in 2020 was 14.15 million yuan; The corresponding net losses were 112 million yuan and 91.628 million yuan respectively.<b>As of the first quarter of 2021, the company's loss scale has doubled from the same period last year to 35.258 million yuan</b>。 It is foreseeable that in a short period of time, the company's \"burning money\" research and development situation will continue.</p>","source":"gelonghui_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AGCO Baifa IPO in Hong Kong: annual loss of 91.63 million, product has not yet been commercialized</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAGCO Baifa IPO in Hong Kong: annual loss of 91.63 million, product has not yet been commercialized\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">格隆汇</strong><span class=\"h-time small\">2021-07-06 18:35</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Shanghai AGCO Baifa Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as \"AGCO Baifa\") submitted a listing prospectus to the Hong Kong Stock Exchange, Bank of America,<a href=\"https://laohu8.com/S/600030\">CITIC Securities</a>And China Renaissance Capital as joint sponsors, with Deloitte as its auditor.</p><p>Since its establishment in 2014, AGCO Baifa has carried out<b>8 rounds of financing</b>。 In the latest C + round of financing, in January 2021, the company introduced Hillhouse Venture Capital and TPG to jointly lead the investment, and 8 investment institutions including Wanrong Hongtu, Ruihua Investment, and Yanyuan Yaoshang participated in the investment.<b>After financing, the company's valuation reached 3.87 billion yuan</b>。</p><p>Before the IPO, in terms of the company's shareholding structure, Dr. Jim Zhen WU held 19.58% of the shares through the wholly-owned Prots Excel, 4.99% of the shares through the wholly-owned Million Joy, and 2.65% of the shares through the 99.99% of the shares. Owns 27.22% of the shares; The four employee stock ownership plan platforms hold a total of 7.96% of the shares; Among institutional investors,<b>Qiming Venture Capital holds the largest share, reaching 11.11%</b>； Taifu Capital holds a total of 7.84% of the shares through Golden Trend and HarmonySky; Morningside Capital holds 7.51% of the shares through Yaoyang Biotechnology;<b>Hillhouse Capital and TPG each hold 4.99% of the company's equity</b>In addition, other shareholders hold approximately 31% of the shares.</p><p><img src=\"https://static.tigerbbs.com/7b431d82c25aa99e56762dcca708a2c2\" tg-width=\"1118\" tg-height=\"676\" referrerpolicy=\"no-referrer\"></p><p>In terms of business, AGCO Baifa, as an innovative biopharmaceutical company, focuses on discovering and developing new therapies to meet the unmet medical needs of respiratory and lung diseases.</p><p>At present, AGCO Baifa has developed<b>Pipeline of 9 drug candidates</b>, the core products include a three-drug RSV drug portfolio led by Ziresovir, and a three-drug anti-fibrotic drug portfolio focusing on AK3280. In addition, the company has a number of drugs under development in the fields of pulmonary fibrosis and inflammation, liver and other diseases that are in the preclinical or clinical stage, and there is still a long time before they are launched.</p><p><img src=\"https://static.tigerbbs.com/1abd4768a9678b36257ed9350d5fec2e\" tg-width=\"1064\" tg-height=\"669\" referrerpolicy=\"no-referrer\"></p><p>In 2020, the global RSV drug market was USD 1.8 billion,<b>Expected to grow to $1.8 billion by 2030</b>, with a compound annual growth rate of 21.4%. At present,<b>There is no effective treatment for RSV on the market</b>。 Ziresovir, which is being developed by AGCO Baifa, is the world's first RSV drug to successfully complete a phase II proof-of-concept clinical trial for hospitalized infants and young children.</p><p>Clinical trials have shown that after taking multiple doses of Ziresovir, patients have strong antiviral effects. Compared with the placebo group, the viral load of the drug treatment group is reduced by up to 98%, showing good efficacy and safety. At present,<b>AK0529 drug (Ziresovir) for pediatric RSV is already in clinical phase III and is expected to submit a new drug application to the State Food and Drug Administration in the second half of 2022 and be launched domestically in 2023.</b></p><p><img src=\"https://static.tigerbbs.com/adefd4a0d734b6768bbede484a81ad6e\" tg-width=\"773\" tg-height=\"704\" referrerpolicy=\"no-referrer\"></p><p>For now, AGCO Baifa has not yet launched any products for commercialization.<b>Still in the red</b>。 The prospectus shows that the company had no revenue in 2019, and its revenue in 2020 was 14.15 million yuan; The corresponding net losses were 112 million yuan and 91.628 million yuan respectively.<b>As of the first quarter of 2021, the company's loss scale has doubled from the same period last year to 35.258 million yuan</b>。 It is foreseeable that in a short period of time, the company's \"burning money\" research and development situation will continue.</p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.gelonghui.com/p/473496\">格隆汇</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","relate_stocks":{"HSI":"恒生指数"},"source_url":"http://www.gelonghui.com/p/473496","is_english":false,"share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","article_id":"2149333886","content_text":"上海爱科百发生物医药技术股份有限公司（以下简称“爱科百发”）向港交所递交上市招股说明书，美银、中信证券和华兴资本担任联席保荐人，德勤为其审计师。\n自2014年成立以来，爱科百发共开展了8轮融资。在最新的C+轮融资中，2021年1月，公司引入高瓴创投、TPG联合领投，万容红土、瑞华投资、燕园姚商等8家投资机构参与投资，融资后公司估值达到38.7亿元。\nIPO前，公司股权架构方面，Jim Zhen WU博士通过全资拥有的Prots Excel持股19.58%，通过全资拥有的Million Joy持股4.99%，通过持股99.99%的爱尔凯持股2.65%，合计拥有股份27.22%；4个雇员持股计划平台合计持股7.96%；机构投资者中，启明创投持股占比最大，达11.11%；泰福资本通过Golden Trend、HarmonySky合计持股7.84%；晨兴资本通过耀阳生物科技持股7.51%；高瓴资本、TPG各持有公司4.99%股权，除此之外，其他股东持股约31%。\n\n业务方面，爱科百发作为一家创新生物制药公司，专注于发现和开发新型疗法，以应对呼吸系统和肺部疾病方面未被满足的医疗需求。\n目前，爱科百发已开发了9种候选药物的产品管线，核心产品包括以Ziresovir为首的三项药物RSV药品组合，以及以AK3280为重点的三项药物的抗纤维化药品组合。除此之外，公司在肺纤维化和炎症、肝脏及其他疾病领域还有多款在研药品处于临床前或临床阶段，离上市还有很长的时间。\n\n2020年，全球RSV药物市场为18亿美元，预计到2030年将增长至18亿美元，年复合增长率为21.4%。目前，市场上还没有有效的RSV治疗方法。而爱科百发正研发的Ziresovir是全球首款成功完成住院婴幼儿II期概念验证临床试验的RSV药物。\n临床试验显示，多剂量服用Ziresovir后，患者体内有强抗病毒作用，与安慰剂组相比，药物治疗组的病毒载量最多减少98%，显示出良好的疗效及安全性。目前，针对儿童RSV的AK0529药物（Ziresovir）已处于临床III期，预计将于2022年下半年向国家药监局提交新药申请，并于2023年在国内上市。\n\n就目前而言，爱科百发尚未有产品上市商业化，仍处于亏损状态。招股书显示，公司2019年无营收，2020年营收为1415万元；相对应的净亏损分别为1.12亿元、9162.8万元。截至2021年一季度，公司亏损规模较上年同期扩大1倍至3525.8万元。可以预见的是，短时间内，公司“烧钱”研发的状况仍将持续。","news_type":1,"symbols_score_info":{"HSI":0.9}},"isVote":1,"tweetType":1,"viewCount":1852,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
